CIDP Benefits Persist in Efgartigimod Open-Label Extension

Chronic Inflammatory Demyelinating Polyradiculoneu News

CIDP Benefits Persist in Efgartigimod Open-Label Extension
Chronic Inflammatory Demyelinating PolyneuropathyCIDP
  • 📰 Medscape
  • ⏱ Reading Time:
  • 41 sec. here
  • 4 min. at publisher
  • 📊 Quality Score:
  • News: 27%
  • Publisher: 55%

FDA-approved efgartigimod represents the first novel, precision mechanism of action in more than 30 years for CIDP.

MONTREAL — An open-label extension study of subcutaneous efgartigimod PH20 to treat chronic inflammatory demyelinating polyneuropathy showed durability of functional improvements to week 24, with no new safety signals.the coformulation of efgartigimod alfa and hyaluronidase-qvfc based on results of the pivotal phase 3 ADHERE study.

"Evidence supports a role for pathogenic IgG in the pathogenesis of CIDP, although in most patients, a specific antibody is currently not detectable," said Allen. In Stage B, 27.9% of participants on efgartigimod PH20 relapsed compared with 53.6% of those on placebo and 9.2% having more serious TEAEs.

Efgartigimod can be self-administered or administered by a caregiver at home. Among study participants who took part in ADHERE+, 37% were successfully trained to self-administer the infusion, with an additional 6% of caregivers completing this training, added Allen.Sara Austin, MD, a neurologist at Seton Brain and Spine Neurology and associate professor at Dell Medical School, University of Texas, Austin, Texas, said the neuromuscular community has looked forward to these results.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Medscape /  🏆 386. in US

Chronic Inflammatory Demyelinating Polyneuropathy CIDP

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Combo Therapy for CIDP Suggests Benefit Despite Clotting RiskCombo Therapy for CIDP Suggests Benefit Despite Clotting RiskOPTIC trial investigators reported sustained improvements in CIPD with intravenous immunoglobulin plus methylprednisolone after early termination for thromboembolic events.
Read more »

Puerto Rico issues an island-wide heat advisory for the first time as power outages persistPuerto Rico issues an island-wide heat advisory for the first time as power outages persistMeteorologists have for the first time issued a heat advisory for the entire island of Puerto Rico as it struggles with chronic power outages.
Read more »

Puerto Rico issues an island-wide heat advisory for the first time as power outages persistPuerto Rico issues an island-wide heat advisory for the first time as power outages persistMeteorologists have for the first time issued a heat advisory for the entire island of Puerto Rico as it struggles with chronic power outages.
Read more »

In France’s rebranded far right, flashes of antisemitism and racism persistIn France’s rebranded far right, flashes of antisemitism and racism persistAhead of French elections, vitriol and innuendo from National Rally candidates amplify doubts about how much the party of Marine Le Pen has truly evolved.
Read more »

European markets open mixed as inflation worries persist; H&M plunges 14%European markets open mixed as inflation worries persist; H&M plunges 14%European stocks opened mixed Thursday as global inflation worries continue to rattle markets.
Read more »

European markets head for negative open as inflation worries persistEuropean markets head for negative open as inflation worries persistEuropean stocks are expected to open in negative territory Thursday as global inflation worries continue to rattle markets.
Read more »



Render Time: 2025-02-16 11:32:52